Intellia Therapeutics fights to recover as institutional investors bet big on its future
Intellia Therapeutics closed 2025 with its stock price near a 52-week low, trading at just $8.99. Despite a sharp decline from its peak of $28.25, major investors stepped in during the final weeks of the year to bolster the company’s position on the stock market.
The biotech firm’s share price tumbled throughout 2025, ending the year roughly 68% below its 52-week high. Regulatory challenges contributed to the drop, leaving the stock struggling to regain momentum.
In late December, ARK Invest made a notable move by purchasing 145,153 shares, worth around $1.33 million. This followed earlier investments from other major institutions, including Regeneron Pharmaceuticals, Vanguard Group, State Street Corp, and Millennium Management, which had increased its holdings in mid-November. Over the past 12 months, total institutional inflows into Intellia reached $305.49 million. The fresh capital injections aimed to stabilize the stock around the $9 mark as 2026 began. Analysts at Zacks Investment Research rated the stock a 'Hold' as of December 31, reflecting cautious optimism amid the volatility. With a market capitalization of about $1.09 billion, the company now faces a critical test of whether the late-year buying spree can sustain its price recovery on the stock market.
Intellia Therapeutics enters 2026 with renewed institutional backing but a significantly weakened share price. The stock’s ability to hold above $9 in the coming weeks will indicate whether the recent investments can offset its regulatory and market challenges.
